0

Comorbidities Persist for the 90% of Patients With MASH and No Cirrhosis

Comorbidities Persist for the 90% of Patients With MASH and No Cirrhosis

Comorbidities Persist for the 90% of Patients With MASH and No Cirrhosis

By December 10, 2024

Comorbidities Persist for the 90% of Patients With MASH and No Cirrhosis

Comorbidities Persist for the 90% of Patients With MASH and No Cirrhosis

Current Status
Not Enrolled
Price
Free
Get Started

This course discusses the research that highlighted the significant costs associated with MASH, particularly in the United States and Europe, and how this economic burden can be mitigated.

Click CE Information to start the course. Post Test and Evaluation must be completed to earn certificate of completion.